-+ 0.00%
-+ 0.00%
-+ 0.00%

The stock price of Capricorn Therapeutics fell 48.5% after a panel of experts from the US Food and Drug Administration voted to reject the company's treatment for heart disease caused by Duchenne muscular dystrophy.

Zhitongcaijing·07/30/2026 13:33:31
Listen to the news
The stock price of Capricorn Therapeutics fell 48.5% after a panel of experts from the US Food and Drug Administration voted to reject the company's treatment for heart disease caused by Duchenne muscular dystrophy.